Drugs / 4-MUST
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07594977 | Jan 2026 → Jun 2027 expected | biliary dyskinesia, cholecystitis | Valenta Pharm JSC | Recruiting | No outcome recorded |
| Phase 1 | NCT06342804 | Mar → Dec 2024 | cholecystitis | Valenta Pharm JSC | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06842966 | Oct 2024 → Dec 2026 expected | biliary dyskinesia, cholecystitis | Valenta Pharm JSC | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07595003 | Dec 2025 → Dec 2027 expected | biliary dyskinesia, cholecystitis | Valenta Pharm JSC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-MUST | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06842966 ↗ |
| Known as | trimebutine 4-methylumbelliferyl sulfate | “128 mg tablets containing trimebutine 4-methylumbelliferyl sulfate (4-MUST)” NCT07594977 ↗ |
| Route | Oral | “single oral administration” NCT06342804 ↗ |